Home|Journals|Articles by Year|Audio Abstracts
 

Original Research



Dobesilate: A potential therapy for long-covid?

Pedro Cuevas, Antonio Manquillo, Javier Angulo, Guillermo Giménez-Gallego.




Abstract
Cited by 0 Articles

On the basis of the involvement of fibroblast growth factor (FGF) and vascular endothelial growth factor (VEGF) in inflammation and vascular changes in COVID-19, we hypothesized that Dobesilate, a demonstrated anti-FGF and anti-VEGF drug might be beneficial for treating COVID-19 patients. We conducted a study and recruited 13 patients with long-COVID syndrome from one center. Dobesilate (Doxium® 1g, twice a day for 15 days) shows clinical efficacy by improving symptoms in these patients.

Key words: SARS-CoV-2, COVID-19, Long-COVID, Dobesilate






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.